577968-62-8

Upstream product

• 1476-11-5 Z-1,4-dichlorobutene 
• 577968-61-7 3-benzyloxy-4-difluoromethoxyphenylacetonitrile 

Downstream Products

• 581777-67-5 2-(3-benzyloxy-4-difluoromethoxy-phenyl)-4-oxo-2-(2-oxo-ethyl)-butyronitrile 
• 401519-08-2 methyl {4-cyano-4-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]piperidin-1-yl}acetate 
• 401519-11-7 methyl {4-[3-butoxy-4-(difluoromethoxy)phenyl]-4-cyanopiperidin-1-yl}acetate 
• 401519-02-6 methyl {4-[3-(benzyloxy)-4-(difluoromethoxy)phenyl]-4-cyanopiperidin-1-yl}acetate 
• 401519-09-3 methyl {4-cyano-4-[3-(cyclobutylmethoxy)-4-(difluoromethoxy)phenyl]piperidin-1-yl}acetate 
• 401519-07-1 methyl {4-cyano-4-[4-(difluoromethoxy)-3-(2,3-dihydro-1H-inden-2-yloxy)phenyl]piperidin-1-yl}acetate 

Relevant academic research and scientific papers

Highly potent PDE4 inhibitors with therapeutic potential

Synthesis and biological evaluation of piperidine derivatives is reported. The hypothesis that the dose-limiting side effects of PDE4 inhibitors could be mediated via the central nervous system prompted us to design and synthesize a hydrophilic piperidine

PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT

A piperidine derivative of formula (I) (wherein all symbols are as described in the specification.) and an intermediate for the preparation thereof The compound of formula (I) has phosphodiesterase 4 inhibitory activity, and it is useful for the prevention and/or treatment of inflammatory diseases, diabetic diseases, allergic diseases, autoimmune diseases, ocular diseases, osteoporosis, bone fracture, osteoarthritis, obesity, bulimia, depression, Parkinson's disease, dementia, ischemia-reperfusion injury, leukemia, acquired immunodeficiency deficiency syndrome (AIDS), shock, systemically inflammatory responsive diseases (SIRS), etc.